Skin Disorders Video 8: Psoriasis Treatment With Biologics

News
Article

Psoriatic arthritis can be treated with the new TNF-alpha inhibitor biologic drugs, etanercept, adalimumab, or infliximab.

Ted Rosen, MD, Professor of Dermatology at Baylor College of Medicine, offers bite-size pieces of useful clinical information on the “Top 10” skin disorders you see in your daily practice.

Segment 8: Psoriasis

For more webinar videos, click here.

Related Content
Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Sydney Jennings
February 5th 2025
Article

Your daily dose of the clinical news you may have missed.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD Queen’s University

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Grace Halsey
February 4th 2025
Article

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

Grace Halsey
January 27th 2025
Article

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis

Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis

Grace Halsey
January 23rd 2025
Article

There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.

Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis / image credit ©isavira/stock.adobe.com

Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis, Study Suggests

Grace Halsey
January 20th 2025
Article

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

© 2025 MJH Life Sciences

All rights reserved.